Accent is building a highly collaborative team of experienced drug developers, all keenly focused on building the bridge from extraordinary science to life-changing therapies for patients.
Our people are Accent. Their rigor2, patient focus, resolute purpose, adventurous spirits and contagious enthusiasm are what drive us forward.
We set high standards of scientific and business excellence in all that we do. Everyone at Accent is committed to challenging and holding themselves and each other to these standards. We embrace an atmosphere where clear and open communication is paramount to ensuring that every voice is heard, ideas can be debated, and teams have the information they need to do their best work.
Our mission is to translate extraordinary science to life-changing therapies for patients in need. We are driven by compassion for these patients and their families and always keep their needs foremost in our minds.
We consider carefully but act decisively to drive progress forward. Every minute and every dollar are precious, so we expend our energy and resources wisely and empower members of our team to take ownership of key decisions that drive the company forward.
We choose to work at the cutting edge of novel biology that intersects with drug discovery – where true innovation and advances can be made. This is uncharted territory, with many surprises and challenges along the way. We take calculated risks, accept the lessons and growth that these surprises and challenges offer, and welcome the adventure of working at this frontier.
What we are doing is very, very hard and very, very serious. We choose to do this important work in a culture of mutual respect, mutual support, genuine excitement and up-lifting spirit. We make it a priority to have fun each and every day.
Our leadership is composed of seasoned professionals, each with a proven track record of accomplishment in biotechnology. Collectively, our team forms a strong, cohesive partnership with the expertise, resilience, spirit and professionalism required for successful drug development against novel targets.
- Ann Boriack-Sjodin, Ph.D.
- Robert A. Copeland, Ph.D.
President, Co-founder, Chief Scientific Officer
- Nicole Heifner
Chief Financial Officer
- Scott Ribich, Ph.D.
- Jacqueline Wheeler
& Office Manager
Scientific Advisory Board
Our founders and advisors are a well-balanced combination of academic and industrial thought leaders with expertise spanning a diverse range of key scientific and clinical disciplines.
- Karen N. Allen, Ph.D.
- Scott A. Armstrong, M.D., Ph.D.
Dana-Farber Cancer Institute
Harvard Medical School
- Howard Y. Chang, M.D., Ph.D.
- Carl P. Decicco, Ph.D.
- Chuan He, Ph.D.
University of Chicago
- Peter Ho, M.D., Ph.D.
- Allen Oliff, M.D.